| Herth, Felix JF |
| Active, not recruiting | 3 | 1667 | Europe, Canada, Japan, US, RoW | GSK3511294 (Depemokimab), Mepolizumab, Benralizumab, Placebo, Standard of care (SoC), Pre-filled Syringes (PFS) | GlaxoSmithKline, Iqvia Pty Ltd | Asthma | 10/25 | 10/25 | | |
|
RECOVER, NCT05200754: Trial With or Without Infusion of SARS-CoV-2 Antibody Containing Plasma in High-Risk Patients With COVID-19 |
|
|
| Recruiting | 2 | 174 | Europe | Convalescent/Vaccine-boosted Plasma (CP/PVP) | Carsten Müller-Tidow, German Federal Ministry of Education and Research, Institut für Klinische Transfusionsmedizin und Zelltherapie Heidelberg gGmbH | SARS-CoV-2 Infection | 04/22 | 06/22 | | |
NCT06317285: A Study to Evaluate the Efficacy and Safety of GSK3915393 in Participants With Idiopathic Pulmonary Fibrosis (IPF) |
|
|
| Recruiting | 2 | 150 | Europe, Canada, US, RoW | GSK3915393, Placebo | GlaxoSmithKline | Idiopathic Pulmonary Fibrosis | 03/26 | 03/26 | | |
NCT03685526: Cinenses Lung Volume Reduction Reverser System First-in-man Study Treating Patients With Severe Emphysema |
|
|
| Active, not recruiting | N/A | 15 | Europe | Cinenses Lung Volume Reduction Reverser System | Lifetech Scientific (Shenzhen) Co., Ltd. | Emphysema | 10/21 | 08/22 | | |
EFFORT, NCT04520152: Evaluation of the Free Flow Medical Lung Tensioning Device System for the Treatment of Severe Emphysema |
|
|
| Completed | N/A | 14 | Europe | FreeFlowMedical Lung Tensioning Device | University Medical Center Groningen | Emphysema or COPD | 11/23 | 11/23 | | |
| Completed | N/A | 102 | Europe, RoW | AeriSeal, Zephyr Valves, Bronchoscopic Lung Volume Reduction (BLVR), Zephyr System | Pulmonx Corporation | Emphysema, COPD, Severe Emphysema | 10/23 | 10/24 | | |
NCT06035120: An Evaluation of the AeriSeal System for CONVERTing Collateral Ventilation Status in Patients with Severe Emphysema |
|
|
| Recruiting | N/A | 200 | Europe, US, RoW | AeriSeal System | Pulmonx Corporation | Emphysema, Pulmonary, Emphysema or COPD | 06/27 | 03/28 | | |
IAB-1, NCT05087641: A Multicenter, Prospective Trial of the IAB in Adults Suffering From COPD/Emphysema |
|
|
| Active, not recruiting | N/A | 20 | Europe, RoW | IAB System | Pulmair Medical, Inc. | Emphysema, Pulmonary Disease, Chronic Obstructive | 04/24 | 01/27 | | |
RheSolve, NCT04677465: Clinical Study of the RheOx Bronchial Rheoplasty System in Treating the Symptoms of Chronic Bronchitis |
|
|
| Active, not recruiting | N/A | 270 | Europe, US | RheOx Bronchial Rheoplasty, Sham Procedure | Gala Therapeutics, Inc. | Chronic Bronchitis | 05/24 | 10/25 | | |
| Active, not recruiting | N/A | 464 | Europe, US | Targeted Lung Denervation (TLD), TLD, TLD Therapy, Optimal Medical Care | Nuvaira, Inc. | COPD | 10/24 | 09/28 | | |
| Recruiting | N/A | 100 | Europe | RheOx | Gala Therapeutics, Inc. | Chronic Bronchitis, COPD | 12/24 | 12/25 | | |
NCT06655428: The REDUCE EU Study - Endobronchial Thermal Liquid Ablation (ETLA) for the Treatment of Emphysema |
|
|
| Recruiting | N/A | 30 | Europe | Endobronchial Therman Liquid Ablation (ETLA), Bronchoscopic lung volume reduction | Morair Medtech, LLC | Emphysema or COPD, Emphysema, Emphysema, Pulmonary, COPD, COPD (Chronic Obstructive Pulmonary Disease) | 02/26 | 05/26 | | |
| Recruiting | N/A | 300 | Europe | Bronchoscopic Thermal Vapor Ablation, BTVA, InterVapor | Uptake Medical Technology, Inc. | Emphysema or COPD | 12/27 | 12/30 | | |
NCT05717192: BENTO - Bronchoscopic Lung Volume Reduction in Severe Emphysema Using Thermoablation |
|
|
| Recruiting | N/A | 224 | Europe | InterVapor®-System | IHF GmbH - Institut für Herzinfarktforschung | Emphysema or Chronic Obstructive Pulmonary Disease | 04/26 | 12/27 | | |
| Michl, Patrick |
| Active, not recruiting | 2 | 352 | Europe, Canada, US | tisotumab vedotin, TIVDAK, pembrolizumab, KEYTRUDA®, carboplatin, cisplatin | Seagen Inc., Genmab, Merck Sharp & Dohme LLC | Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Exocrine Pancreatic Cancer, Carcinoma, Squamous Cell of Head and Neck | 02/26 | 11/26 | | |
| Completed | N/A | 400 | Europe | FoundationOne®CDx and FoundationOne®Liquid | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Roche Pharma AG | Hepatocellular Cancer, Cholangiocarcinoma, Gallbladder Cancer, Pancreatic Cancer, Oesophageal Cancer, Stomach Cancer | 08/24 | 08/24 | | |
| Active, not recruiting | N/A | 1000 | Europe | | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Hepatocellular Cancer, Cholangiocarcinoma, Gallbladder Cancer, Pancreatic Cancer, Oesophageal Cancer, Stomach Cancer | 05/32 | 05/32 | | |
| Büchner-Steudel, Petra |
| Completed | N/A | 400 | Europe | FoundationOne®CDx and FoundationOne®Liquid | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Roche Pharma AG | Hepatocellular Cancer, Cholangiocarcinoma, Gallbladder Cancer, Pancreatic Cancer, Oesophageal Cancer, Stomach Cancer | 08/24 | 08/24 | | |
| Active, not recruiting | N/A | 1000 | Europe | | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Hepatocellular Cancer, Cholangiocarcinoma, Gallbladder Cancer, Pancreatic Cancer, Oesophageal Cancer, Stomach Cancer | 05/32 | 05/32 | | |
| Zipprich, Alexander |
NCT05056220: Personalized Long-term Human Albumin Treatment in Patients With Decompensated Cirrhosis and Ascites |
|
|
| Recruiting | 3 | 240 | Europe | Human albumin, sodium chloride | Aleksander Krag, EASL - CLIF Consortium | Decompensated Cirrhosis and Ascites | 03/25 | 04/25 | | |
EVALUATION, NCT06814990: Acquisition of Cardiac Function Parameters in MRI and Echocardiography in Patients with Ethyltoxic Liver Cirrhosis and Transjugular Intrahepatic Portosystemic Shunt (TIPSS) Placement |
|
|
| Recruiting | N/A | 80 | Europe | Cardiac MRI, Blood samples, Echocardiography | Stephanie Gräger, Jena University Hospital | MASLD, Liver Cirrhosis, Alcoholic, Cirrhosis of Liver, Heart Decompensation, TIPS | 04/27 | 04/27 | | |
| Braun, Thorsten |
| Recruiting | 3 | 124 | Europe | EPREX, Epoetin alfa | Groupe Francophone des Myelodysplasies | Myelodysplastic Syndromes | 05/22 | 05/24 | | |
| Recruiting | 3 | 550 | Europe, Canada, US, RoW | Tamibarotene, SY-1425, Placebo, Azacitidine | Syros Pharmaceuticals | Myelodysplastic Syndromes | 11/24 | 02/29 | | |
| Recruiting | 3 | 322 | Europe, Canada, US | Crenolanib, Crenolanib besylate, Cytarabine, Mitoxantrone, Placebo Oral Tablet, Fludarabine, Idarubicin, G-CSF | Arog Pharmaceuticals, Inc. | Relapsed/Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations | 10/24 | 10/24 | | |
HOVON 156 AML, NCT04027309 / 2018-000624-33: A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy |
|
|
| Active, not recruiting | 3 | 777 | Europe, RoW | Gilteritinib, ASP2215, Midostaurin, Rydapt | Stichting Hemato-Oncologie voor Volwassenen Nederland, Deutsch-Österreichische Studiengruppe Akute Myeloische Leukämie (AMLSG), Astellas Pharma Global Development, Inc. | Acute Myeloid Leukemia, Myelodysplastic Syndrome With Excess Blasts-2 | 10/25 | 06/33 | | |
LOTIS 5, NCT04384484 / 2020-000241-14: Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma |
|
|
| Active, not recruiting | 3 | 440 | Europe, Canada, Japan, US, RoW | Loncastuximab Tesirine, Zynlonta, ADCT-402, Rituximab, Gemcitabine, Oxaliplatin | ADC Therapeutics S.A., ADC Therapeutics SA | Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma | 06/25 | 06/28 | | |
|
|
|
| Recruiting | 2b | 102 | Europe, Canada, US, RoW | DPX-Survivac, maveropepimut-S, Pembrolizumab, MK-3475, Keytruda, CPA, Intermittent, low-dose cyclophosphamide, Procytox, Cytoxan | ImmunoVaccine Technologies, Inc. (IMV Inc.), Merck Sharp & Dohme LLC | Relapsed Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-cell Lymphoma | 10/24 | 04/25 | | |
PONAZA, NCT03895671: : A COMBINATION OF PONATINIB AND 5-AZACITIDINE IN CHRONIC MYELOGENOUS LEUKAEMIA IN ACCELERATED PHASE OR IN MYELOID BLAST CRISIS |
|
|
| Recruiting | 2 | 40 | Europe | Ponatinib, Azacitidine | Versailles Hospital | CHRONIC MYELOGENOUS LEUKAEMIA IN ACCELERATED PHASE, CHRONIC MYELOGENOUS LEUKAEMIA IN MYELOID BLAST CRISIS | 12/23 | 12/24 | | |
| Active, not recruiting | 2 | 95 | Europe, US | Tamibarotene, Venetoclax, Venclexta, Azacitidine, Vidaza | Syros Pharmaceuticals, Syros Pharmaceuticals, Inc. | Acute Myeloid Leukemia | 04/28 | 04/28 | | |
| Recruiting | 2 | 74 | Europe | Teclistamab, JNJ-64007957, Daratumumab, Lenalidomide | University Hospital, Lille, Janssen Pharmaceutica N.V., Belgium | Multiple Myeloma | 05/25 | 09/30 | | |
| Completed | 2 | 42 | Europe | CPX-351 | French Innovative Leukemia Organisation, Acute Leukemia French Association, French Intergroup of Myeloproliferative syndromes | Acute Myeloid Leukemia, Myeloproliferative Syndrome | 10/23 | 12/23 | | |
AVENHIR, NCT05768711: Azacitidine Combined With Venetoclax in Patients With Higher-risk Chronic Myelomonocytic Leukemia |
|
|
| Recruiting | 2 | 44 | Europe | Venetoclax, ABT-199 | Groupe Francophone des Myelodysplasies, AbbVie | Chronic Myeloid Leukemia | 02/26 | 10/28 | | |
| Recruiting | 2 | 50 | Europe | Gemtuzumab ozogamicine - Cytarabine - Gilteritinib, Mylotarg - Aracytine - Xospata | Centre Antoine Lacassagne, Acute Leukemia French Association | AML | 03/27 | 03/27 | | |
ALFA2101, NCT05260528: CPX-351 vs Intensive Chemotherapy in Patients With de Novo Intermediate or Adverse Risk AML Stratified by Genomics |
|
|
| Recruiting | 2 | 210 | Europe | Cytarabine and Idarubicin, CPX-315 | Centre Hospitalier Universitaire de Nice, Jazz Pharmaceuticals, Acute Leukemia French Association | Acute Myeloid Leukemia | 10/27 | 10/27 | | |
ACTIW, NCT02767063: Therapies in Combination or Sequentially With Tyrosine Kinase Inhibitors (TKIs) in Chronic Phase Chronic Myelogenous Leukemia Patients in CCR |
|
|
| Recruiting | 1/2 | 100 | Europe | Pioglitazone, Avelumab | Versailles Hospital | Leukemia, Myeloid, Chronic-Phase | 11/22 | 06/23 | | |
SALMA, NCT05580861: Sulfasalazine in AML Treated by Intensive Chemotherapy: Elderly Patients-first Line Treatment |
|
|
| Recruiting | 1/2 | 64 | Europe | Sulfasalazine | Assistance Publique - Hôpitaux de Paris | Acute Myeloid Leukemia | 11/25 | 12/26 | | |
NCT05782127: Oral Azacitidine Combined with Venetoclax in Previously Untreated Higher-risk Myelodysplastic Syndromes |
|
|
| Recruiting | 1/2 | 36 | Europe | Onureg + Venetoclax, CC-486 + ABT-199 | Groupe Francophone des Myelodysplasies, Bristol-Myers Squibb, AbbVie | Untreated Myelodysplastic Syndrome | 11/25 | 11/28 | | |
NCT02629692 / 2016-001754-18: Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment of Ph+ CML Resistant/Intolerant to ≥3 Prior CML Therapies |
|
|
| Active, not recruiting | 1/2 | 122 | Europe, US, RoW | Vodobatinib (K0706) capsules | Sun Pharma Advanced Research Company Limited | Healthy (For Part A), Chronic Myeloid Leukemia (for Part B and C) | 08/26 | 08/26 | | |
NCT05181735: Study Evaluating Combination of Luspatercept in LR-MDS Without RS Having Failed or Being Ineligible to ESA |
|
|
| Recruiting | 1/2 | 150 | Europe | Luspatercept Injection [Reblozyl], ACE-536, Eprex, Epoietin alfa | Groupe Francophone des Myelodysplasies, Celgene | MDS, Myelodysplastic Syndromes | 05/27 | 11/27 | | |
ALFAPPP, NCT04777916: Prospective Non-interventional Study of Adult Patients With Acute Myeloid Leukemia (AML) |
|
|
| Recruiting | N/A | 2500 | Europe | | Acute Leukemia French Association | Acute Myeloid Leukemia (AML) | 04/32 | 04/46 | | |
| Recruiting | N/A | 3000 | Europe | Biobanking | Assistance Publique - Hôpitaux de Paris | Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, High-risk Myelodysplastic Syndrome, Secondary Myelofibrosis in Myeloproliferative Disease, Myeloproliferative Neoplasm, Unclassifiable | 03/42 | 03/42 | | |
DYNHAEMICS, NCT05304156: Single-cell Dynamic Profiling in Adults With Newly Diagnosed Acute Myeloid Leukemia Treated With Intensive Chemotherapy. A THEMA Study" |
|
|
| Recruiting | N/A | 200 | Europe | Biobanking blood and bone marrow specimens | Assistance Publique - Hôpitaux de Paris | Acute Myeloid Leukemia | 04/26 | 05/26 | | |
| Renzis, Benoit de |
| Recruiting | 3 | 124 | Europe | EPREX, Epoetin alfa | Groupe Francophone des Myelodysplasies | Myelodysplastic Syndromes | 05/22 | 05/24 | | |
| Recruiting | 3 | 550 | Europe, Canada, US, RoW | Tamibarotene, SY-1425, Placebo, Azacitidine | Syros Pharmaceuticals | Myelodysplastic Syndromes | 11/24 | 02/29 | | |
NCT03643042: Impact of 2 Transfusion Strategies on Quality of Life of Multitransfused Patients With Low-risk Myelodysplastic Syndrome |
|
|
| Terminated | N/A | 11 | Europe | Transfusion | Lille Catholic University | Myelodysplastic Syndromes, Transfusion-dependent Anemia | 09/22 | 03/23 | | |
| Müller, Lutz P |
GRAPPA, NCT05153226: GvHD Prophylaxis in Unrelated Donor HCT: Randomized Trial Comparing PTCY Versus ATG |
|
|
| Active, not recruiting | 3 | 640 | Europe | Cyclophosphamide, all brands, ATG, ATG Grafalon | DKMS gemeinnützige GmbH | Graft Vs Host Disease, Peripheral Blood Stem Cell Transplantation, AML, MDS, MDS/MPN, CMML | 06/25 | 12/26 | | |
AlloRelapseMM, NCT05675319: Allogeneic Stem Cell Transplantation vs. Conventional Therapy as Salvage Therapy for Relapsed / Progressive Patients With Multiple Myeloma After First-line Therapy |
|
|
| Recruiting | 3 | 482 | Europe | Allogeneic Stem Cells, carfilzomib/lenalidomide/dexamethasone (KRD), elotuzumab/lenalidomide/dexamethasone (ERD), daratumumab/bortezomib/dexamethasone (DVD), daratumumab/lenalidomide/dexamethasone (DRD), ixazomib/lenalidomide/dexamethasone (IRD), pomalidomide/bortezomib/dexamethasone (PVD), carfilzomib/daratumumab/dexamethasone (KDD), Autologous Stem Cells, daratumumab/pomalidomide/dexamethasone (DPD), isatuximab/carfilzomib/dexamethasone (Isa-KD), selinexor/bortezomib/dexamethasone (SVD) | Universitätsklinikum Hamburg-Eppendorf, Gemeinsamer Bundesausschuss (G-BA), Staburo GmbH | Multiple Myeloma | 03/28 | 03/33 | | |
| Completed | 2/3 | 98 | Europe | Peripheral blood stem cells, PBSC | DKMS gemeinnützige GmbH | AML, ALL, MDS | 04/24 | 04/24 | | |
NCT03188874: Clinical AML Registry and Biomaterial Database of the Study Alliance Leukemia (SAL) |
|
|
| Recruiting | N/A | 15000 | Europe | | Technische Universität Dresden | Acute Myeloid Leukemia (AML) | 09/30 | 09/30 | | |
| Kiani, Alexander |
TRIANGLE, NCT02858258: ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma |
|
|
| Recruiting | 3 | 870 | Europe | R-CHOP/R-DHAP, rituximab, CHOP, DHAP, Ibrutinib (Induction), Imbruvica, ASCT conditioning, THAM or BEAM, Ibrutinib (Maintenance) | Prof. Dr. M. Dreyling (co-chairman), LMU Klinikum | Mantle Cell Lymphoma | 05/21 | 05/26 | | |
|
| Active, not recruiting | 3 | 450 | Europe, Japan, US, RoW | Regorafenib, Stivarga, Nivolumab, Opdivo, Docetaxel, Taxotere, Paclitaxel, Abraxane, Irinotecan, Camptosar, Trifluridine/Tipracil, Lonsurf | Australasian Gastro-Intestinal Trials Group, Bayer, Bristol-Myers Squibb, University of Sydney, Academic and Community Cancer Research United, Taiwanese Cooperative Oncology Group, Frankfurter Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, National Cancer Center Hospital East, Syneos Health | Gastro-Oesophageal Cancer | 06/25 | 06/26 | | |
NCT05008809: Post-resection/Ablation Chemotherapy in Patients With Metastatic Colorectal Cancer (FIRE-9 - PORT / AIO-KRK-0418) |
|
|
| Recruiting | 3 | 507 | Europe | mFOLFOX6, Folinic acid, Oxaliplatin, 5-fluorouracil (FU), mFOLFOXIRI, Folinic acid, Oxaliplatin, 5-FU, Irinotecan, FOLFIRI, Folinic acid, 5-FU, CAPOX, Capecitaine, Oxaliplatin | Dominik Paul Modest, German Research Foundation, Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Colorectal Cancer | 11/27 | 11/30 | | |
NCT03530267: Aflibercept and 5-FU vs. FOLFOX as 1st Line Treatment for Elderly or Frail Elderly Patients With Met. Colorectal Cancer |
|
|
| Completed | 2 | 124 | Europe | Aflibercept + mLV5FU2, mFOLFOX7 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, STABIL - Statistische und Biometrische Lösungen, Trium Analysis Online GmbH, Sanofi | Colorectal Cancer | 02/24 | 02/24 | | |
| Recruiting | 2 | 140 | Europe, US, RoW | KER-050 | Keros Therapeutics, Inc., Keros Therapeutics, Inc. | Myelodysplastic Syndromes, Cytopenia | 06/25 | 11/25 | | |
|
|
INFINITY, NCT04389541: Clinical Research Platform on Decision Making and Clinical Impact of Biomarker-Driven Precision Oncology |
|
|
| Completed | N/A | 499 | Europe | | iOMEDICO AG, Bristol-Myers Squibb, Roche Pharma AG | Advanced Solid Tumors or Hematologic Malignancies | 06/23 | 06/23 | | |
| Completed | N/A | 400 | Europe | FoundationOne®CDx and FoundationOne®Liquid | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Roche Pharma AG | Hepatocellular Cancer, Cholangiocarcinoma, Gallbladder Cancer, Pancreatic Cancer, Oesophageal Cancer, Stomach Cancer | 08/24 | 08/24 | | |
LePaLuMo, NCT06252233: Improvement of Quality of Life (QoL) Using Preference-Oriented QoLMonitoring in Patients with Lung Cancer |
|
|
| Recruiting | N/A | 220 | Europe | patient- and physician-centered QoL monitoring, Placebo | University of Bayreuth, University of Regensburg, Tumor Center Regensburg, Center for Quality Management and Health Services Research, G-BA Innovationsfonds, University Hospital Regensburg, Center for Clinical Trials, Bavarian Cancer Registry, Bavarian Health and Food Safety Authority | Lung Cancer, Quality of Life | 02/25 | 08/25 | | |
NCT03188874: Clinical AML Registry and Biomaterial Database of the Study Alliance Leukemia (SAL) |
|
|
| Recruiting | N/A | 15000 | Europe | | Technische Universität Dresden | Acute Myeloid Leukemia (AML) | 09/30 | 09/30 | | |
| Krug, Sebastian |
| Active, not recruiting | 2 | 45 | Europe | Cabozantinib | Karsten Gavenis | Neuroendocrine Tumors, Neuroendocrine Carcinoma | 09/24 | 10/24 | | |
| Completed | N/A | 400 | Europe | FoundationOne®CDx and FoundationOne®Liquid | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Roche Pharma AG | Hepatocellular Cancer, Cholangiocarcinoma, Gallbladder Cancer, Pancreatic Cancer, Oesophageal Cancer, Stomach Cancer | 08/24 | 08/24 | | |
| Active, not recruiting | N/A | 1000 | Europe | | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Hepatocellular Cancer, Cholangiocarcinoma, Gallbladder Cancer, Pancreatic Cancer, Oesophageal Cancer, Stomach Cancer | 05/32 | 05/32 | | |
| Taschner, Christian |
TECNO, NCT05499832: Safety and Efficacy of Intra-arterial Tenecteplase for Noncomplete Reperfusion of Intracranial Occlusions |
|
|
| Recruiting | 3 | 156 | Europe | Tenecteplase | Insel Gruppe AG, University Hospital Bern | Ischemic Stroke | 07/25 | 10/25 | | |
| Not yet recruiting | N/A | 220 | Europe | | University of Freiburg | Chronic Subdural Hematoma | 06/26 | 12/26 | | |
| Active, not recruiting | N/A | 530 | Europe, Canada, US | endovascular thrombectomy (EVT), solitaire X, Standarad medical care | Dr. Michael D Hill, University of Calgary | Acute Ischemic Stroke | 12/25 | 06/26 | | |
| Al-Ali, Haifa Kathrin |
ROP-ET, NCT06514807: A Study to Evaluate the Efficacy and Safety of Ropeginterferon Alfa-2b in Essential Thrombocythaemia Patients |
|
|
| Active, not recruiting | 3 | 117 | Europe, RoW | Ropeginterferon alfa-2b (BESREMi®) | AOP Orphan Pharmaceuticals AG | Essential Thrombocythaemia | 03/28 | 03/28 | | |
| Recruiting | 3 | 550 | Europe, Canada, US, RoW | Tamibarotene, SY-1425, Placebo, Azacitidine | Syros Pharmaceuticals | Myelodysplastic Syndromes | 11/24 | 02/29 | | |
| Recruiting | 3 | 322 | Europe, Canada, US | Crenolanib, Crenolanib besylate, Cytarabine, Mitoxantrone, Placebo Oral Tablet, Fludarabine, Idarubicin, G-CSF | Arog Pharmaceuticals, Inc. | Relapsed/Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations | 10/24 | 10/24 | | |
| Active, not recruiting | 2 | 30 | Europe | Fedratinib Oral Capsule [Inrebic], Nivolumab | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Prof. F. Heidel, MH Hannover, Celgene International II S.á.r.l. | Primary Myelofibrosis, Secondary Myelofibrosis | 12/25 | 06/26 | | |
| Recruiting | N/A | 617 | Europe, RoW | | FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS, GlaxoSmithKline | Myelofibrosis | 12/25 | 12/28 | | |
| Recruiting | N/A | 500 | Europe, RoW | Data collection and quality of life questionnaire | Centre Leon Berard | Cancer, Cancer Metastatic, NTRK Gene Fusion Overexpression, NTRK Family Gene Mutation, ATIC-ALK Fusion Protein Expression, ALK Fusion Protein Expression, BCR-FGFR1 Fusion Protein Expression, ROS1 Gene Translocation, COL1A1-PDGFB Fusion Protein Expression, RET Gene Translocation, Gene Fusion, ROS Gene Translocation, BRAF Gene Rearrangement, FGFR2 Gene Translocation, FGFR3 Gene Translocation, NTRK1 Gene Translocation | 06/25 | 06/25 | | |
| Eisenmann, Stephan |
COSTAR Lung, NCT04655976 / 2020-003433-37: Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy |
|
|
| Active, not recruiting | 3 | 758 | Europe, Canada, Japan, US, RoW | Cobolimab, Dostarlimab, Docetaxel | GlaxoSmithKline | Lung Cancer, Non-Small Cell | 04/25 | 10/25 | | |
| Completed | N/A | 15 | Europe, RoW | SenseGuard | NanoVation | COPD Exacerbation | 05/22 | 05/23 | | |
NCT06035120: An Evaluation of the AeriSeal System for CONVERTing Collateral Ventilation Status in Patients with Severe Emphysema |
|
|
| Recruiting | N/A | 200 | Europe, US, RoW | AeriSeal System | Pulmonx Corporation | Emphysema, Pulmonary, Emphysema or COPD | 06/27 | 03/28 | | |
| Recruiting | N/A | 300 | Europe | Bronchoscopic Thermal Vapor Ablation, BTVA, InterVapor | Uptake Medical Technology, Inc. | Emphysema or COPD | 12/27 | 12/30 | | |
NCT05717192: BENTO - Bronchoscopic Lung Volume Reduction in Severe Emphysema Using Thermoablation |
|
|
| Recruiting | N/A | 224 | Europe | InterVapor®-System | IHF GmbH - Institut für Herzinfarktforschung | Emphysema or Chronic Obstructive Pulmonary Disease | 04/26 | 12/27 | | |
| Walldorf, Jens |
FRESCO, NCT03843385: Transfer of FRozen Encapsulated Multidonor Stool Filtrate for Active Ulcerative COlitis |
|
|
| Recruiting | 3 | 174 | Europe | encapsulated faecal microbiota filtrate, FMFT, encapsulated faecal microbiota, FMT, Placebo, Encapsulated sterile saline | Andreas Stallmach, German Federal Ministry of Education and Research | Ulcerative Colitis, Inflammatory Bowel Diseases | 01/25 | 07/26 | | |
LUCENT-URGE, NCT05767021: A Study of Mirikizumab (LY3074828) in Participants With Moderately to Severely Active Ulcerative Colitis |
|
|
| Active, not recruiting | 3 | 160 | Europe, US, RoW | Mirikizumab, LY3074828 | Eli Lilly and Company | Ulcerative Colitis, Ulcerative Colitis Chronic | 08/24 | 09/25 | | |
| Recruiting | 3 | 1063 | Europe, Canada, Japan, US, RoW | Mirikizumab, LY3074828 | Eli Lilly and Company | Ulcerative Colitis | 07/26 | 12/27 | | |
|
| Jobe, Robert L |
CorCinch-HF, NCT04331769: Clinical Evaluation of the AccuCinch® Ventricular Restoration System in Patients Who Present with Symptomatic Heart Failure with Reduced Ejection Fraction (HFrEF): the CORCINCH-HF Study |
|
|
| Recruiting | N/A | 400 | Europe, US, RoW | AccuCinch Ventricular Restoration System, Guideline-Directed Medical Therapy | Ancora Heart, Inc. | Heart Failure with Reduced Ejection Fraction (HFrEF), Dilated Cardiomyopathy | 12/26 | 12/30 | | |
PROTECT IV, NCT04763200: Impella®-Supported PCI in High-Risk Patients With Complex Coronary Artery Disease and Reduced Left Ventricular Function |
|
|
| Recruiting | N/A | 1252 | Europe, Canada, US | Impella CP® / Impella CP® with SmartAssist® / Impella 2.5®, IABP Intra-aortic balloon pump | Abiomed Inc. | Left Ventricular Dysfunction, Coronary Artery Disease | 03/26 | 10/27 | | |
| Cohen, Jose Enrique |
FIRST, NCT04034810: Safety and Efficacy of Silk Vista and Silk Vista Baby Flow Diverter for Intracranial Aneurysm Treatment |
|
|
| Active, not recruiting | N/A | 234 | Europe, RoW | Intracranial aneurysm treated with Silk vista and silk vista baby | Balt Extrusion | Intracranial Aneurysm | 03/23 | 11/27 | | |
| Recruiting | N/A | 170 | Europe, RoW | Endovascular treatment of unruptured aneurysms with p64 MW HPC Flow Modulation Device | Phenox GmbH | Intracranial Aneurysm | 12/24 | 12/24 | | |
| Lechardeur, Jessica |
| Active, not recruiting | 3 | 430 | Europe, Canada, US, RoW | Pelabresib, Ruxolitinib, Placebo | Constellation Pharmaceuticals | Myelofibrosis, Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis | 08/23 | 12/27 | | |
|
|
|
|
|
| Recruiting | 3 | 550 | Europe, Canada, US, RoW | Tamibarotene, SY-1425, Placebo, Azacitidine | Syros Pharmaceuticals | Myelodysplastic Syndromes | 11/24 | 02/29 | | |
| Edouart, Geoffrey |
| Recruiting | 3 | 550 | Europe, Canada, US, RoW | Tamibarotene, SY-1425, Placebo, Azacitidine | Syros Pharmaceuticals | Myelodysplastic Syndromes | 11/24 | 02/29 | | |
| Recruiting | 2b | 102 | Europe, Canada, US, RoW | DPX-Survivac, maveropepimut-S, Pembrolizumab, MK-3475, Keytruda, CPA, Intermittent, low-dose cyclophosphamide, Procytox, Cytoxan | ImmunoVaccine Technologies, Inc. (IMV Inc.), Merck Sharp & Dohme LLC | Relapsed Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-cell Lymphoma | 10/24 | 04/25 | | |
| Active, not recruiting | 2 | 95 | Europe, US | Tamibarotene, Venetoclax, Venclexta, Azacitidine, Vidaza | Syros Pharmaceuticals, Syros Pharmaceuticals, Inc. | Acute Myeloid Leukemia | 04/28 | 04/28 | | |
| Dierks, Christine |
| Completed | 3 | 721 | Europe, RoW | study part 1 - dose daunorubicin, induction cycles | Technische Universität Dresden, University Hospital Dresden, Masaryk University | Leukemia, Myelocytic, Acute | 04/22 | 04/22 | | |
| Recruiting | 2 | 146 | Europe | Venetoclax plus Azacitidine, standard of care chemotherapy plus gemtuzumab ozogamicin | Technische Universität Dresden, University Hospital Heidelberg, AbbVie | Acute Myeloid Leukemia | 09/28 | 09/28 | | |
| Recruiting | 1/2 | 214 | Europe | MODULE: conventional chemotherapy (Cytarabine+Daunorubicin) in combination with midostaurin+GO, Rydapt, Mylotarg, MAGNOLIA-trial: Midostaurin associated with conventional chemotherapy (AraC+DNR)+GO, MAGNOLIA-trial: conventional chemotherapy (AraC+DNR)+GO, MAGMA-trial:GO associated with conventional chemotherapy (AraC+DNR)+Midostaurin, MAGMA-trial: conventional chemotherapy (AraC+DNR)+Midostaurin | Technische Universität Dresden, Novartis Pharmaceuticals, Pfizer | Acute Myeloid Leukemia | 04/27 | 04/28 | | |
| Recruiting | N/A | 9000 | Europe | | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Sarcoma, Sarcoma,Soft Tissue, Sarcoma of Bone, Carcinosarcoma | 01/38 | 01/38 | | |
| Gabor, Szabo |
AKITA, NCT05126303: Efficacy and Safety of RMC-035 in Subjects at High Risk for Acute Kidney Injury Following Open-Chest Cardiac Surgery |
|
|
| Terminated | 2 | 177 | Europe, Canada, US, RoW | RMC-035, ROSgard, Placebo | Guard Therapeutics AB | Acute Kidney Injury | 04/23 | 07/23 | | |
POINTER, NCT06475274: A Phase 2b Dose Finding Study of RMC-035 in Participants Undergoing Open-chest Cardiac Surgery |
|
|
| Recruiting | 2 | 161 | Europe, Canada | RMC-035, Placebo | Guard Therapeutics AB | Kidney Injury Following Open-Chest Cardiac Surgery | 10/25 | 10/25 | | |
| Böhm, Johannes |
AKITA, NCT05126303: Efficacy and Safety of RMC-035 in Subjects at High Risk for Acute Kidney Injury Following Open-Chest Cardiac Surgery |
|
|
| Terminated | 2 | 177 | Europe, Canada, US, RoW | RMC-035, ROSgard, Placebo | Guard Therapeutics AB | Acute Kidney Injury | 04/23 | 07/23 | | |
POINTER, NCT06475274: A Phase 2b Dose Finding Study of RMC-035 in Participants Undergoing Open-chest Cardiac Surgery |
|
|
| Recruiting | 2 | 161 | Europe, Canada | RMC-035, Placebo | Guard Therapeutics AB | Kidney Injury Following Open-Chest Cardiac Surgery | 10/25 | 10/25 | | |
| Schweitzer, Nora |
| Completed | N/A | 400 | Europe | FoundationOne®CDx and FoundationOne®Liquid | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Roche Pharma AG | Hepatocellular Cancer, Cholangiocarcinoma, Gallbladder Cancer, Pancreatic Cancer, Oesophageal Cancer, Stomach Cancer | 08/24 | 08/24 | | |
| Active, not recruiting | N/A | 1000 | Europe | | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Hepatocellular Cancer, Cholangiocarcinoma, Gallbladder Cancer, Pancreatic Cancer, Oesophageal Cancer, Stomach Cancer | 05/32 | 05/32 | | |
| Damm, Marko |
NCT04511455: Cabozantinib for Patients with Hepatocellular Carcinoma (HCC) Refractory to First Line Treatment |
|
|
| Completed | 2 | 22 | Europe | Cabozantinib | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Ipsen | Hepatocellular Carcinoma Non-resectable, Metastatic Hepatocellular Carcinoma | 12/24 | 12/24 | | |
| Recruiting | N/A | 124 | Europe | TIPS, Standard of Care, Terlipressin + Albumin | Jena University Hospital, German Research Foundation, University Hospital Halle (Saale) | Cirrhosis, Liver, Hepatorenal Syndrome, Acute Kidney Injury, Ascites Hepatic | 06/25 | 06/26 | | |
| Moritz, Ute |
| Completed | N/A | 400 | Europe | FoundationOne®CDx and FoundationOne®Liquid | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Roche Pharma AG | Hepatocellular Cancer, Cholangiocarcinoma, Gallbladder Cancer, Pancreatic Cancer, Oesophageal Cancer, Stomach Cancer | 08/24 | 08/24 | | |
